All translations

Enter a message name below to show all available translations.

Found 2 translations.

Name	Current message text
^h English (en)	====Dipeptidyl peptidase-4 inhibitors==== {{Main\|Dipeptidyl peptidase-4 inhibitor}} GLP-1 analogs resulted in weight loss and had more gastrointestinal side-effects, while in general [[dipeptidyl peptidase-4]] (DPP-4) inhibitors were weight-neutral and increased risk for infection and headache, but both classes appear to present an alternative to other antidiabetic drugs. However, weight gain and/or hypoglycemia have been observed when [[dipeptidyl peptidase-4 inhibitor]]s were used with sulfonylureas; effects on long-term health and morbidity rates are still unknown.
^h Japanese (ja)	====ジペプチジルペプチダーゼ-4阻害剤==== {{Main/ja\|Dipeptidyl peptidase-4 inhibitor/ja}} GLP-1アナログは体重減少をもたらし、胃腸の副作用がより多かったが、一般的に[[dipeptidyl peptidase-4/ja\|ジペプチジルペプチダーゼ-4]]（DPP-4）阻害薬は体重中立で、感染症や頭痛のリスクを増加させたが、両クラスとも他の抗糖尿病薬の代替となるようである。しかし、[[dipeptidyl peptidase-4 inhibitor/ja\|ジペプチジルペプチダーゼ-4阻害薬]]をスルホニル尿素薬と併用した場合、体重増加や低血糖が観察されている；長期的な健康状態や罹患率への影響はまだ不明である。